Attributable mortality of carbapenem-resistant Klebsiella pneumoniae infections in a prospective matched cohort study in Italy, 2012-2013

The Journal of Hospital Infection
A HoxhaStudy Working Group

Abstract

In Italy, infections with carbapenem-resistant Klebsiella pneumoniae (CRKP) have increased markedly since 2009, creating unprecedented problems in healthcare settings and limiting treatment options for infected patients. To assess the attributable mortality due to CRKP in ten Italian hospitals and to describe the clinical characteristics of patients with an invasive CRKP and carbapenem-susceptible K. pneumoniae (CSKP) infection. We conducted a matched cohort study, and calculated crude and attributable mortality for CRKP. The attributable mortality was calculated by subtracting the crude mortality rate of the patients with CSKP from the crude mortality rate of the patients with CRKP. We also described the clinical characteristics of CRKP and CSKP patients and analysed the determinants of mortality by using conditional Poisson regression. The study included 98 patients, 49 with CRKP and 49 with CSKP. CRKP patients had undergone more invasive procedures and also tended to have more serious conditions, measured by higher Simplified Acute Physiology Score II. The attributable mortality of CRKP at 30 days was 41%. CRKP patients were three times more likely to die within 30 days [matched incidence rate ratio (mIRR): 3.0; 95% confiden...Continue Reading

References

Jan 1, 1991·Antimicrobial Agents and Chemotherapy·M WatanabeS Mitsuhashi
Jan 19, 2007·International Journal of Antimicrobial Agents·George L DaikosHelen Malamou-Lada
Nov 1, 2008·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Gopi PatelDavid P Calfee
Aug 25, 2009·The American Journal of Medicine·Bonnie L MeatherallKevin B Laupland
Aug 29, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Abraham BorerMichael Sherf
Oct 27, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Eleni MouloudiNikoleta Gritsi-Gerogianni
Mar 15, 2011·Diagnostic Microbiology and Infectious Disease·Elizabeth A NeunerDavid van Duin
Oct 23, 2012·Antimicrobial Resistance and Infection Control·Mari KanervaOuti Lyytikäinen
Dec 18, 2012·The Journal of Infectious Diseases·Elizabeth B HirschVincent H Tam
Aug 13, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tara N Palmore, David K Henderson
Jun 25, 2014·Emerging Infectious Diseases·Matthew E FalagasKonstantinos Z Vardakas

❮ Previous
Next ❯

Citations

Dec 19, 2015·The Journal of Hospital Infection·J W Gray, N Mahida
Dec 3, 2016·Pathogens and Global Health·Fethiye AkgulHakan Leblebicioglu
Mar 31, 2017·Annals of Clinical Microbiology and Antimicrobials·Liangfei XuXiaoling Ma
Nov 28, 2017·Annals of Clinical Microbiology and Antimicrobials·David M JacobsGauri G Rao
Mar 17, 2019·Expert Review of Anti-infective Therapy·Maddalena GiannellaPierluigi Viale
Jun 28, 2019·Antimicrobial Resistance and Infection Control·Marjolein C PersoonJuliëtte A Severin
Nov 16, 2016·SpringerPlus·Bulent DurduTuran Aslan
May 13, 2020·Antimicrobial Resistance and Infection Control·Yulia Rosa SaharmanJuliëtte A Severin
Feb 28, 2017·Antimicrobial Resistance and Infection Control·Deborah De GeyterIngrid Wybo
Mar 27, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Romney M HumphriesZachary Aaron Rubin
Jul 6, 2018·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Shuangshuang YangLiping Zhang
Dec 9, 2020·Antimicrobial Resistance and Infection Control·Esther E AvendanoEilish McCann
Nov 27, 2020·Frontiers in Cellular and Infection Microbiology·Shuguang ZhangTongwen Sun
Dec 29, 2020·Frontiers in Cellular and Infection Microbiology·Enea Gino Di DomenicoFabrizio Ensoli
Jul 28, 2021·The Journal of Antimicrobial Chemotherapy·Robin BruyndonckxUNKNOWN ESAC-Net study group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.